Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer-Reference-Cited by-同舟云学术

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

Published:2019-12-19 Issue:25 Volume:381 Page:2403-2415
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Coleman Robert L.¹,Fleming Gini F.¹,Brady Mark F.¹,Swisher Elizabeth M.¹,Steffensen Karina D.¹,Friedlander Michael¹,Okamoto Aikou¹,Moore Kathleen N.¹,Efrat Ben-Baruch Noa¹,Werner Theresa L.¹,Cloven Noelle G.¹,Oaknin Ana¹,DiSilvestro Paul A.¹,Morgan Mark A.¹,Nam Joo-Hyun¹,Leath Charles A.¹,Nicum Shibani¹,Hagemann Andrea R.¹,Littell Ramey D.¹,Cella David¹,Baron-Hay Sally¹,Garcia-Donas Jesus¹,Mizuno Mika¹,Bell-McGuinn Katherine¹,Sullivan Danielle M.¹,Bach Bruce A.¹,Bhattacharya Sudipta¹,Ratajczak Christine K.¹,Ansell Peter J.¹,Dinh Minh H.¹,Aghajanian Carol¹,Bookman Michael A.¹

Affiliation:

1. From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C.); University of Chicago Medicine (G.F.F.) and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University (D.C.), Chicago, and AbbVie, North Chicago (D.M.S., B.A.B., S.B., C.K.R., P.J.A., M.H.D.) — all in Illinois; NRG Oncology Statistical and Data Center, Roswell Park Cancer Institute, Buffalo (M.F.B.), and Memorial Sloan Kettering Cancer Center, New York (K.B.-M., C.A.) — both in New York; University of...

Funder

AbbVie

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1909707

Cited by 613 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. The Poor Prognosis of Acquired Secondary Platinum Resistance in Ovarian Cancer Patients;Cancers;2024-02-02

3. Frontline Management of Advanced Epithelial Ovarian Cancer: A Comprehensive Statement by the Africa Middle East Cancer Inter-group [AMCI];Current Women s Health Reviews;2024-02

4. Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer;Gynecologic Oncology;2024-02

5. Efficacy and safety of neoadjuvant chemotherapy containing anti-angiogenic drugs, immunotherapy, or PARP inhibitors for ovarian cancer;Critical Reviews in Oncology/Hematology;2024-02